MoneyWorks4Me

Concord Drugs - Quaterly Results

13 Feb 2024 Evaluate
The sales is pegged at Rs. 126.24 millions for the December 2023 quarter. The mentioned figure indicates decline with the sales recorded at Rs. 135.27 millions during the year-ago period.The Net Loss for the quarter ended December 2023 is Rs. -2.39 millions as compared to Net Profit of Rs. 4.54 millions of corresponding quarter ended December 2022The company reported a degrowth in operating Profit to 5.62 millions from 14.45 millions.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202312 202212 % Var 202312 202212 % Var 202303 202203 % Var
Sales 126.24 135.27 -6.68 288.02 397.82 -27.60 513.23 590.57 -13.10
Other Income 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
PBIDT 5.62 14.45 -61.11 34.97 36.13 -3.21 43.52 56.94 -23.57
Interest 4.32 4.49 -3.79 12.12 12.07 0.41 16.25 16.81 -3.33
PBDT 1.30 9.96 -86.95 22.85 24.06 -5.03 27.27 40.13 -32.05
Depreciation 3.85 3.80 1.32 11.48 12.96 -11.42 16.03 17.65 -9.18
PBT -2.55 6.16 -141.40 11.37 11.10 2.43 11.24 22.48 -50.00
TAX -0.16 1.62 -109.88 3.63 2.86 26.92 2.33 6.54 -64.37
Deferred Tax -0.11 -0.05 120.00 -0.54 -0.38 42.11 -1.14 -0.18 533.33
PAT -2.39 4.54 -152.64 7.74 8.24 -6.07 8.91 15.94 -44.10
Equity 100.00 87.44 14.36 100.00 87.44 14.36 93.16 87.44 6.54
PBIDTM(%) 4.45 10.68 -58.33 12.14 9.08 33.69 8.48 9.64 -12.05
Peers
Company Name CMP
Sun Pharma. Inds. 1810.00
Dr. Reddys Labs. 1200.10
Cipla 1346.85
Lupin 2029.00
Zydus Lifesciences 1145.25
View more..